The name of the company "Amarantus Bioscience Holdings" gives everyone a clue, but it wasn't until the Gerald/Jason revenue conflict and the purchase of ESS that the model really began to sink in. It isn't intuitive to not care about revenue in a traditional sense.

Interesting.